Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although methods of viral attenuation in plasma-derived clotting-factor concentrates have improved, there is still a possibility that such concentrates may transmit certain blood-borne viruses. For this reason, the use of recombinant DNA-derived factor VIII (which is virus-free) to treat hemophilia A has generated considerable interest. METHODS: We conducted a multicenter trial in previously untreated children with hemophilia A. They received recombinant factor VIII for all treatment or for prophylaxis and were evaluated at their respective clinics at intervals of no more than three months. RESULTS: Between January 1, 1989, and July 1, 1992, 95 patients who could be evaluated received recombinant factor VIII. By September 1, 1992, they had received the concentrate exclusively for 2.4 months to 3.5 years (median, 1.5 years). All responded well, with no treatment failures. A total of 3315 infusions were administered; there were three reports of minor adverse reactions. Inhibitor antibodies to factor VIII developed in 16 of 81 patients tested for them, after a median of nine days of exposure to factor VIII treatment. Inhibitor titers were or became low in 9 of the 16 patients despite continued episodic treatment with the concentrate. Inhibitors disappeared completely in 4 patients and remained at a low level (< 10 Bethesda units) in 5 patients receiving episodic treatment. CONCLUSIONS: Transient or low levels of inhibitor, as observed in this study, may represent part of the natural history of hemophilia in infants. In view of the transient nature and lower concentration of the inhibitors detected and the generally satisfactory response to treatment, the benefits of recombinant factor VIII for the treatment of hemophilia seem to outweigh the risks.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Individual Comparisons by Ranking Methods
Wilcoxon, F. (1945) · Biometrics Bulletin · doi:10.2307/3001968 · Cited by 15,354
Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
Ehrenforth, S., Kreuz, W., Linde, R., Funk, M., Güngor, T., Krackhardt, B., Kornhuber, B., & Scharrer, I. (1992) · The Lancet · doi:10.1016/0140-6736(92)90874-3 · Cited by 605
MASSIVE FACTOR-VIII INFUSION IN HÆMOPHILIAC WITH FACTOR-VIII INHIBITOR, HIGH RESPONDER
Brackmann, H. H., & Gormsen, J. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90871-6 · Cited by 270
Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A
Schwartz, R. S., Abildgaard, C. F., Aledort, L. M., Arkin, S., Bloom, A. L., Brackmann, H. H., Brettler, D. B., Fukui, H., Hilgartner, M. W., Inwood, M. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199012273232604 · Cited by 267
Self-citationMcMillan, C., Shapiro, S., Whitehurst, D., Hoyer, L., Rao, A., & Lazerson, J. (1988) · Blood · doi:10.1182/blood.v71.2.344.344 · Cited by 169
Use of Recombinant Antihemophilic Factor in the Treatment of Two Patients with Classic Hemophilia
White, G. C., McMillan, C. W., Kingdon, H. S., & Shoemaker, C. B. (1989) · New England Journal of Medicine · doi:10.1056/nejm198901193200307 · Cited by 164
Azzi, A., Ciappi, S., Zakvrzewska, K., Morfini, M., Mariani, G., & Mannucci, P. M. (1992) · American Journal of Hematology · doi:10.1002/ajh.2830390315 · Cited by 164
FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting
Fulcher, C., de Graaf Mahoney, S., & Zimmerman, T. (1987) · Blood · doi:10.1182/blood.v69.5.1475.1475 · Cited by 162
Pathophysiology of hemolysis in glucose-6-phosphate dehydrogenase deficiency.
Arese, P., & FLORA, A. D. (1990) · PubMed · Cited by 152
Scandella, D. H., Mattingly, M., de Graaf, S., & Fulcher, C. (1989) · Blood · doi:10.1182/blood.v74.5.1618.1618 · Cited by 134
Induction of Immune Tolerance to Factor VIII in Hemophiliacs With Inhibitors
Ewing, N. P. (1988) · JAMA · doi:10.1001/jama.1988.03720010043038 · Cited by 122
SYMPTOMATIC PARVOVIRUS B19 INFECTION AND HEAT-TREATED FACTOR IX CONCENTRATE
Lyon, D., Chapman, C. S., Martin, C., Brown, K. E., Clewley, J. P., Flower, A. E., & Mitchell, V. E. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92488-4 · Cited by 85
Schwarzinger, I., Pabinger, I., Korninger, C., Haschke, F., Kundi, M., Niessner, H., & Lechner, K. (1987) · American Journal of Hematology · doi:10.1002/ajh.2830240303 · Cited by 74
Addiego, J. E., Gomperts, E. D., Shu-Len, L., Bailey, P., Courter, S. G., Lee, M. L., Neslund, G., Kingdon, H. S., & GRIFFITH, M. J. (1992) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1648373 · Cited by 71
Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome
Rasi, V., & Ikkala, E. (1990) · British Journal of Haematology · doi:10.1111/j.1365-2141.1990.tb06370.x · Cited by 62
Kleim, J., Bailly, E., Schneweis, K. E., Brackmann, H., Hammerstein, U., Hanfland, P., van Loo, B., & Oldenburg, J. (1990) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1647314 · Cited by 58
Effect of frequent factor VIII replacement on the level of factor VIII antibodies in haemophiliacs
Rizza, C. R., & Matthews, J. M. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb03857.x · Cited by 51
Mannucci, P. M., & Colombo, M. (1989) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646630 · Cited by 42
Lusher, J. M. (1987) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1987.tb30987.x · Cited by 39
Self-citationHepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate
Berntorp, E. E., Nilsson, I. M., Ljung, R., & Widell, A. (1990) · The Lancet · doi:10.1016/0140-6736(90)93075-z · Cited by 35
Factor VIII inhibitors: A clinical overview
White, G., McMillan, C. W., Blatt, P. M., & Roberts, H. R. (1982) · American Journal of Hematology · doi:10.1002/ajh.2830130410 · Cited by 32
Antibody to Hepatitis G Mrus after a Vapour-Heated Factor Vlll Goncentrate
Mannucci, P. M., Zanetti, A. R., Colombo, M., Chistolini, A., Biasi, R. D., Musso, R., Tamponi, G., & the Study Group of the Fondazione deii–Emofilia (1990) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1647291 · Cited by 32
Hoelzer, D. T., Seipelt, G., & Ganser, A. (1991) · PubMed · Cited by 27
Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C
Lusher, J. M. (1991) · Annals of Hematology · doi:10.1007/bf01703244 · Cited by 25
Self-citationInduction of immune tolerance to factor VIII in hemophiliacs with inhibitors
Np, E. (1988) · JAMA · doi:10.1001/jama.259.1.65 · Cited by 13
Epidemic of Factor VIII Inhibitors Linked to Factor VIII-P
Vermylen, J., & Peerlinck, K. (1991) · Acta Clinica Belgica · doi:10.1080/17843286.1991.11718201 · Cited by 10
Genetic characterization of recombinant BHK-21 cells expressing factor VIII.
Chan, S. Y., & Lembach, K. J. (1991) · PubMed · Cited by 8
Preclinical and in vitro studies of recombinant factor VIII.
Fournel, M. (1991) · PubMed · Cited by 8
Brazell, C., McClue, S. J., Preston, G. C., King, B., & Stahl, S. M. (1991) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-199102000-00003 · Cited by 7
Research works printed but not linked: 10
- 1991, Blood, 78, 1409
- Chan SY, 1991, Semin Hematol, 28, 10
- Klein U, 1991, Semin Hematol, 28, 17
- Kasper CK, 1975, Thromb Diath Haemorrh, 34, 869
- Hoyer LW, 1984, Prog Clin Biol Res, 150, 73
- Hoyer LW, 1991, Blood Coagul Fibrinolysis, 2, 11
- Lusher JM, 1991, Blood Coagul Fibrinolysis, 2, 1
- Gill FM, 1984, Prog Clin Biol Res, 150, 19
- 1990, Semin Hematol, 27, 1
- Fournel MA, 1991, Semin Hematol, 28, 22
Cited by
Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease
Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E., & Desnick, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450102 · Cited by 1,559
The hemophilias--from royal genes to gene therapy
Mannucci, P. M., & Tuddenham, E. G. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442307 · Cited by 1,110
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Desnick, R. J., Brady, R., Barranger, J., Collins, A. J., Germain, D. P., Goldman, M., Grabowski, G., Packman, S., & Wilcox, W. R. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-4-200302180-00014 · Cited by 766
“However, in contrast to the clinical experience with protein replacement therapy in hemophilia (51, 52), there is no evidence that antibody formation alters efficacy (12, 13).”
ResultAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Metadata
- Authors
- Lusher, J. M., Arkin, S., Abildgaard, C. F., & Schwartz, R. S.
- Affiliations
- Children's Hospital of Michigan (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of California, Davis (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1993-02-18
- Volume
- 328
- Issue
- 7
- Pages
- 453-459
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2337290468
- Cited by
- 476
- References
- 29
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 3 · 2023: 4 · 2022: 7 · 2021: 8 · 2020: 10 · 2019: 10 · 2018: 9 · 2017: 13 · 2016: 14 · 2015: 19 · 2014: 12 · 2013: 15 · 2012: 13
- FWCI
- 15.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- recombinant factor VIII, hemophilia A, treatment-naive patients, factor VIII inhibitors, prophylaxis, episodic treatment, children, treatment safety, treatment efficacy, blood-borne virus transmission
- MeSH terms
- Antibodies, Antibody Formation, Factor VIII, Hemophilia A, Humans, Infant, Recombinant Proteins, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.